Palvella Therapeutics, Inc.
151.34USD
-0.9400 (-0.62%)
Computing valuation metrics…
Valuation
P/E (TTM)
—
P/E (Forward)
—
EV/EBITDA
573.39x
EV/Revenue
1454.27x
P/S (TTM)
1622.86x
P/B
10.12x
FCF Yield
0.68%
Dividend Yield
0.00%
Gross Margin
0.00%
Operating Margin
-4270.78%
Net Margin
-4563.31%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| PVLAPalvella Therapeutics, Inc. | $2.19B | — | 573.39x | 0.68% | -100.00% | 0.00% |
| VRTXVertex Pharmaceuticals Incorporated | $132.08B | 30.32x | 25.13x | 1.99% | 12.50% | — |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $83.43B |
| 20.06x |
| 16.08x |
| 3.67% |
| 16.70% |
| 0.45% |
| ARGXargenx SE | $62.33B | 38.24x | 968.98x | 1.22% | 59.30% | — |
| MRNAModerna, Inc. | $54.14B | — | — | 0.55% | 2.10% | — |
| RPRXRoyalty Pharma plc | $35.01B | 32.58x | 24.44x | -3.41% | 16.50% | 1.47% |
| ROIVRoivant Sciences Ltd. | $30.20B | — | — | -3.73% | -33.50% | — |
| INCYIncyte Corporation | $25.22B | 15.85x | 10.67x | 4.68% | 37.70% | — |
| BNTXBioNTech SE | $24.65B | — | — | -1.01% | -59.50% | — |